Johnson & Johnson (NYSE:JNJ) Vision said today that the FDA approved its iDesign Refractive Studio for planning Lasik eye procedures.
iDesign uses a three-second scan to perform a wavefront analysis of how light travels inside the eye and maps the topography of the cornea to customize Lasik treatments for myopia, hyperopia, mixed astigmatism and presbyopic myopia, Santa Ana, Calif.-based J&J Vision said.
“As a practicing ophthalmologist for more than 25 years, I know firsthand the importance of taking precise measurements and tailoring Lasik procedures for each patient,” medical & clinical affairs VP Dr. Jonathan Talamo said in prepared remarks. “The new iDesign Refractive Studio provides surgeons with the ability to deliver one-of-a-kind custom laser vision correction for each patient to have excellent visual outcomes following their Lasik procedure.”
“The ability to perform monovision Lasik with iDesign Refractive Studio will benefit many patients and I’m proud to have been a part of that clinical investigation,” added Dr. Robert Maloney of the Maloney Vision Institute in Los Angeles. “More patients are experiencing better quality outcomes with Lasik procedures and wavefront-guided treatments. This technology is truly revolutionizing how we measure and treat refractive errors.”
The iDesign system is slated to hit the U.S. market during the third quarter, the company said.
